Special

Biocapital – access to investments

EuropeanBiotechnology

Science & Industry News

Nº 5 | Volume 12 | 2013 | 10.00 € | ISSN 1618-8276 | A 60711 |

ceNTRal eUROpeRoche dismantles Applied Science business unit

NORTHeRN eUROpe

Bavarian Nordic lands US$228m contract with US government

WeSTeRN eUROpe

Genticel bags investment for therapeutic HPV vaccine

SOUTHeRN eUROpe

Italy’s health ministry allows contested stem cell treatments

eaSTeRN eUROpe

Big Data’s role in a100m Polish drug development initiative

ScieNce & TecHNOlOgy

Spanish scientists present list of DNA replication factors

Biosimilars – up or down?

FREE EXCERPT

For life science research only.Not for use in diagnostic procedures.X-TREMEGENE is a trademark of Roche.

Roche Diagnostics GmbHSandhofer Straße 11668305 Mannheim, Germany

© 2013 Roche Diagnostics. All rights reserved.

Demanding Transfection. Easy Solution.

Focus your efforts on discovery. Efficiently transfect difficult cells, including more than 100 cancer cell lines using X-tremeGENE DNA Transfection Reagents.

Free sample and protocols at www.x-tremegene.roche.com

xtremegene_ad_EuroBiotechNews_210x275_rz.indd 1 19.03.2013 16:47:36 Uhr

I n a post-petroleum society, biorefineries – along with the farmers and foresters who source raw materials – are at the heart of

the economy. No matter how you define it, the concept remains the same: converting raw ma-terials into useful products for society. Instead of fossil fuels, the biobased economy employs renewable resources and wastes to produce a series of products useful to society: biofuels, bioenergy, biochemicals, bioplastics and other biomaterials.

The potential social, economic and environ-mental benefits of this model are substantial across Europe. Farmers and foresters would play a pivotal role in enabling the biobased economy’s goals of delivering locally-sourced and produced materials, chemicals, fuels, food and feed. With sustainability at the heart of the biobased econ-omy, growth could be decoupled from resource depletion and environmental degradation. That would in turn boost the EU’s ability to transi-tion more rapidly to a low-carbon and resource-efficient society, and it would further enable the EU to lead and compete in a global biobased econ-omy market that is expected to reach the a200bn mark by 2020. The biobased economy is just the project to propel Europeans onto the path of reindustrial isation and sustainable growth, and to reverse the current investment trend toward other regions of the world. It offers a road back to prosperity across all of the regions in the EU, and creates new jobs that will not simply disappear in the mid to long term. It will build on existing EU strengths and resources, embracing technological and scientific excellence, and creating new and novel partnerships between industries that have thus far remained unconnected. Supplementing food production, the conversion of bio mass into bioproducts will likewise present a chance for the EU27 agricultural and forestry sectors to diver-sify revenues and revitalise rural areas.

For about a year now, industries across sectors have come together to discuss partnership op-portunities with the EU. The resulting effort is called BRIDGE – a proposed “Biobased Indus-tries Public-Private Partnership” in the form of a Joint Technology Initiative (JTI) known as the “Biobased and Renewables Industries for Devel-opment and Growth in Europe.”

BRIDGE is a €3.8bn commitment (EU: €1bn, Private sector: €2.8bn) over the 2014-2020 pe-riod, with a clear strategic research agenda that includes defined focus areas for demonstration projects and a set of flagship initiatives. Research institutes, academia and SMEs have been play-ing and will continue to play a crucial role in the PPP. The same goes for Member States, which will be instrumental in the process – particularly during the project deployment phase. The PPP might have been conceived in Brussels, but it will be implemented at national, regional and local levels across Europe. A Biobased Industries PPP in the form of a JTI is sending the right signals to invest in Europe, as well as to translate the EU’s R&D potential into new, innovative and sustain-able biobased products and markets.

By the end of June 2013, the European Com-mission is scheduled to propose a (recovery) pack-age of JTIs aimed at stimulating growth and jobs and improving the quality of life in Europe. BRIDGE will be among these initiatives. The proposals are to be passed on to the European Par-liament and the Council of the European Union for approval. The Biobased Industries Consorti-um (BIC) is calling on EU legislators to support the Commission JTI proposal for BRIDGE in or-der to unlock the biobased economy potential and trigger more sustainable growth in Europe. B

Euro|Biotech|NewsN º– 5 | Volume 12 | 2013 3

INtro

Editorial

The BRIDGE to a biobased economy in the EU

Dirk Carrez, Executive Director (a.i.), Biobased Industries Consortium (BIC), Brussels

Dirk Carrez is the Coordinator for BIC, an industry consortium that includes more than 40 European companies and organisations from the fields of technology, industry, agriculture and forestry that are preparing the Biobased Industries PPP. Carrez is also the Managing Director of Clever Consult, a consulting firm dedicated to different aspects of the bioeconomy. He is currently the Vice-Chair of the Biotechnology Committee at BIAC(Business and Industry Advisory Committee to the oECD) and the Vice-Chair of the oECD’s task Force for Industrial Biotechnology.

FREE EXCERPT

4 Euro|Biotech|News N º– 5 | Volume 12 | 2013

CIRCULATION

European Biotechnology News is published in co-operation with the following organisations:

Europe: european-biotechnology.net Switzerland: swissbiotech.org

EuroBiotechNews covers the biotechnology sector of the current 27 EU member states, Norway and Switzerland. If you would like to subscribe, please refer to

www.eurobiotechnews.eu

Europe: ebe-biopharma.org

The Netherlands: niaba.nl

Denmark: danskbiotek.dk

Spain: asebio.com France: france-biotech.org Italy: assobiotec.it

Portugal: www.apbio.pt

Europe: cebr.net

Hungary: hungarianbiotech.org

Belgium: bio.be

Council of European BioRegions

Europe: europabio.org

FREE EXCERPT

CMYK

Blue: 100/15/0/35Orange: 0/75/90/0

Sweden: swedenbio.com

EuropeanBiotechnology

Net work

Ireland: ibec.ie/ibia

Norway: biotekforum.no

Finland: fi nbio.net

Germany: biodeutschland.org

Europe: eapb.org

Euro|Biotech|NewsN º– 5 | Volume 12 | 2013 5

coNteNts

INsIght

EFSA rejects GM maize; MEPs delay transparency vote; Heard in Brussels 10

Bioeconomy SME initiative kicks off 12

EMA: pivotal trials shifting away from Europe 13

Study: bioplastics don’t affect use of arable land; IP Flash 14

RegulatoRy affaIRs

Update on clinical trials 16

Breaking news from the EMA 18

ecoNomIc

Focus on newsflow and dividends 19

Stock markets 20

PeRsPectIVes

BIO 2013: Sector grows in US and EU 43

Swiss Biotech remains strong 44

Interview: Lord Howe 46

RegIoNal News

Northern Europe 22

Central Europe 24

Western Europe 26

Southern Europe 28

Eastern Europe 30

Imprint European Biotechnology News is published monthly by: BIOCOM AG, Lützowstr. 33–36, D-10785 Berlin, Germany, Tel.: +49-30-264921-0, Fax: +49-30-264921-11, E-Mail: service@eurobiotechnews.eu; Internet: www.eurobiotechnews.eu, Publisher: Andreas Mietzsch, Editorial Team: Thomas Gabrielczyk (Managing Editor), Derrick Williams (Co-editor), Dr. Patrick Dieckhoff, Dr. Bernd Kaltwaßer, Dr. Martin Laqua; Advertising: Oliver Schnell, +49-30-2649-2145, Advertising USA: Avani Media, Inc. , Leslie Hallanan, Tel.: +1-415-331-2150 , Fax: +1-415-289-0402, E-Mail: leslie@avanimedia.com; Distribution: Marcus Laschke, +49-30-2649-2148; Printed at: Druckhaus Humburg, Bremen; Graphic Design: Michaela Reblin. European Biotechnology Science & Industry News is only regularly available through subscription at BIOCOM AG. Annual subscription fees: € 100.00, Students € 50.00 (subject to proof of enrolment). Prices include VAT, postage & packaging. Ordered subscriptions can be cancelled within 2 weeks directly at BIOCOM AG. The subscription is initially valid for one year. Subscriptions will be renewed automatically for one more year, respectively, unless they are cancelled at least 6 weeks before the date of expiry. Failures of delivery which BIOCOM AG is not responsible for do not entitle the subscriber to delivery or reimbursement of pre-paid fees. Seat of court is Berlin, Germany. As regards contents: individually named articles are published within the sole responsibility of their respective authors. All material published is protected by copyright. No article or part thereof may be reproduced in any way or processed, copied and proliferated by electronic means without the prior written consent of the publisher. Cover Photo: © 123rf.com ® BIOCOM is a registered trademark of BIOCOM AG, Berlin, Germany.

EU pushes the uptake of biosimilars 6

Faced with an uncertain regulatory background and the prospect of trials nearly as demanding as those faced by new clinical substances, many of the segment’s once en-thusiastic pharma proponents have backed out of programmes or put projects on hold. At the BIO congress in Chicago in late April, the European Commission presented its latest study on the sector – which makes a case that the positive aspects of biosimilars for both manufacturers and patients still far outweigh potential downsides.

Cover Story

seRVIces

Partners & Associations 4

Biopeople News from Algeta ASA, Formycon GmbH, Scancell Holdings; Karolinska Development AB, Eyevensys, and Suppremol 47

Company index 48

Events What’s on in May-June 2013 49

Encore 50

SpeCial

Biocapital

Good capital access – for a few companies 33

Making the right call in early-stage funding 34

Interview: Peter Homberg, Dentons 37

India: Pharma innovations at grave risk 40

FREE EXCERPT

10 Euro|Biotech|News N º– 5 | Volume 12 | 2013

INSIGHT EUROPE

Claire Skentelbery, Secretary General of the European Biotechnology Network

Heard in BrusselsM BIO: the synthesis of brilliance

agri-BiotecH

GMO reboundA Brussels/Parma – For the first time since its inception, the European food safety watchdog EFSA has not recommended a GM crop for market. In mid-April, the experts from the agency’s GMO panel stressed that “the applicant failed to sup-ply essential data to allow a full risk as-sessment to take place.” According to the EFSA, the “minimum standards for the design of field trials set out in the EFSA GMO Panel guidance document were not met” for Pioneer’s herbicide -tolerant GM maize 98140, which prevented the panel from carrying out a comparative assessment of the compositional, agro-nomic and phenotypic characteristics and of potential risks to human and ani-mal health. The maize has been genetical-ly modified to express the GAT4621 and Zm-HRA proteins. GAT4621 is a glypho-sate acetyltransferase (GAT) encoded by an optimised form of the gat4621 gene from Bacillus licheniformis that confers tolerance to glyphosate herbicides. The Zm-HRA protein is an acetolactate syn-thase (ALS) encoded by an optimised form of the endogenous ALS gene from Zea mays. It confers tolerance to ALS-in-hibiting herb icides such as chlorimuron and thifensulfuron. B

Brussels – Greetings readers! The observ-ant of you will note that I have strayed far from Brussels in my quest for knowl-edge – I was lucky enough to attend the BIO convention in Chicago in late April, and where better to listen out for sage advice? So what did I hear? Well, apart from the great parties (Belgian café at Buddy Guy’s Legends Club) and my failed chance to win a motorbike in the exhibition hall, I learned something very thought -provoking from my favourite panel – a session focused on synthetic bi-ology and its amazing potential.

I couldn’t possibly name the speakers, but it provided excellent insights into how much time large companies spend on processes that they would rather not have to do. If you run a large company producing novel crops, for example, you want to focus on the stuff you’re good at – producing the final crops themselves – rather than on time and money-consum-ing gene processing tasks. It’s not your speciality, nor is it your firm’s mission. So you have a list of the technologies that you wish existed to make your route to products faster and more effective.

And this is where it got exciting; syn-thetic biology opens up tremendous mar-ket opportunities for smaller companies that can deliver advances in tech tools for processes that large product compa-nies would rather avoid. One such SME (Ginkgo BioWorks) was represented on the speaker panel, and they fill that gap precisely. Their technology can produce organisms to customers’ exact specifi-cations. It was an eye-opening glimpse into how bio logy will soon be engineered from scratch, and why we will no longer just rely on tweaking existing genomes.

These companies are absolutely typical SMEs (Ginkgo was founded by PhD stu-dents). They had to beg, borrow and steal development funds to survive, and show the absolute necessity of genius. Only a

bunch of fearless researchers would have founded this firm and invested in it for five years. I can’t see a large service pro-vider investing the time, money and in-dividual commitment required to bring this technology to fruition.

So the session reminded me of two things. The first is that behind every breakthrough product there is a whole pipeline of breakthrough technologies that enabled it. That’s the beauty of bio-tech of course. Every new field brings multiple commercial opportunities for other new technologies. The second thing – which governments everywhere need to remember – is that SMEs drive applications for inventions, and you ig-nore them at your peril. Ginkgo’s fantas-tic platform was enabled and supported largely through grants. Although it saw little private investment, the firm looks set to help power the next generation of bio -based products. The lesson? If you don’t support innovative SMEs, they can’t deliver.

I’m looking forward to BIO 2014 and hearing from a new wave of SMEs pur-suing amazing technologies that will en-able the next big product. B

clinical trials

Another delayA Strasbourg – The European Parliament’s ENVI Committee has postponed its vote on the draft clinical trials regulation until 29 May 2013. The Committee said it need-ed more time to discuss the over 700 com-promise amendments that have been ta-bled on the European Commission’s draft legislation. In contrast to the Commission, MEPs want to publish full clinical study reports of approved medicines in the EU trials database instead of just a summary of trial results. B

FREE EXCERPT

12 Euro|Biotech|News N º– 5 | Volume 12 | 2013

INSIGHT EUROPE

NewsM Protesting an EU project

Brussels/Munich – GM opponents from the organisation Testbiotech have called on the European Commission to stop the EU project GRACE (GMO Risk Assessment and Communication of Evidence). At the end of April, they claimed the project was not transpar-ent, and suggested that at least eight of its experts have conflicts of interest due to collaborations with agri biotech companies. Testbiotech urged the Commission to stop the project, which is aimed at establishing new standards for GMO risk assessment, until poten-tial conflict of interest issues have been solved. According to its head Jürgen Schiemann, the project will seek to test whether long-term feeding studies should be added to the current GMO risk assessment being carried out for EU food safety watchdog EFSA. At the launch of the project, Schiemann told EuroBiotechNews that he wanted to involve NGOs in setting up the testing criteria, but that some of them would be likely to reject that offer (see Euro-BiotechNews 10/2012).

M Taking aim at kinases

Brussels – Fuelled by a1.1m in EU money, six partners from industry and academia want to discover small-molecule kinase-targeting drugs in the TAKTIC (Translational Kinase Tumour Inhibitor Discovery Consortium) ven-ture. Together with academics from Italy, Israel, and France, the industry partners from SARomics Biostruc-tures (Sweden), Prestwick Chemical (France) and ProQinase GmbH (Ger-many) are to create a new platform for lead compound discovery and test it on three different protein kinases. The consortium plans to licence the result-ing IP to pharma partners.

EUropEaN UNioN

Biotech SMEs snap up EU funds

Bio Base Europe’s pilot plant in the Belgian city of Ghent.

A Brussels –Biotech SMEs involved in the bio-economy initiatives of five European countries are pooling their expertise in an EU project known as BioBaseNWE.

The partners from the Bio Base Europe international non-profit organisation (BE), Ghent Bio-Energy Valley (BE), Bio Base Europe Training Center (NL), RE-WIN/Biobased Innovations (NL), German Cluster Industrielle Biotechnologie, the Galway -based Competence Centre for Bio-refining and Bioenergy (IRL) and the Brit-ish National Non-Food Crops Centre (UK) said in April that they had secured a6.2m from the European Commission.

The overall goal of the three-year Bio Base NWE project is to drive growth and education in the bio-based economy in northwestern Europe. 50% of the project’s a12m overall budget has been granted by the INTERREG IVB North West Eu-rope Programme. The other half comes from Agentschap Ondernemen (BE), Bio-based delta (NL), Provincie Noord-Brabant (NL), Provincie Zeeland (NL), the Nation-al University of Ireland NUI Galway, Ire-land’s Industrial Development Agency (IDA), Enterprise Ireland, and the Nation-al Develop ment Plan Ireland. ”Bio-based products are a growing area of interest for SMEs working in the chemical industry, agro-industry, plastics, fuels, food, textile and the pharma industry,” stressed project

manager Lieve Hoflack. ”However, many SME’s find it difficult to bridge the gap be-tween newly-developed research and the commercial market,” she added.

The network will provide SMEs with fi-nancial support for projects at the Bio Base Europe pilot plant in Ghent. The partner-ship will also develop and deliver pro-grammes and tools for training skilled pro-fessionals for the bio-based industries.

About a2.9m – the lion’s share of the funding – is going to the facilities of the Bio Base Europe Pilot Plant, which grants access for SMEs to its a state-of-the-art facility through a special ‘coupon’ sys-tem. Within Bio Base NWE, SMEs can be granted a coupon worth a10,000 to carry out feasibility analyses, lab work or pilot tests there. According to Bio Base NWE, “this kind of support can be compared to seed capital, as it is intended for assess-ing the feasibility of an innovative bio-based idea”.

Interreg IVB NWE describes the project as a network of bio-innovation agents that will be meeting every three months to dis-cuss its work with SMEs and other stake-holders. They will jointly prepare prod-ucts and activities for the entire project, which includes matchmaking workshops, needs assessment, innovation tools and round tables, training sessions and a sum-mer school. B

© B

BE

FREE EXCERPT

48 Euro|Biotech|News N º– 5 | Volume 12 | 2013

CompaNy aNd adVertiser iNdex

4SC AG (GER) ………………………………… 34

aAbbott GmbH & Co KG (GER) ………………… 47Abbott Laboratories (USA) …………………… 33Abingworth LLP (UK) ………………………… 26Actelion AG (CH) ……………………………… 19Action Pharma A/S (DK) ……………………… 33Activartis Biotech GmbH (A) ………………… 25ADC Therapeutics Sarl (CH) …………………… 44Addex Pharma (CH) …………………………… 18Aeris Capital AG (CH) ………………………… 21Affimed Therapeutics AG (GER) ……………… 34Agennix AG (GER/USA) ……………………… 20AiCuris GmbH & Co KG (GER) ………………… 33Algeta ASA (N) ………………………………… 47Algiax Pharmaceuticals GmbH (GER) ………… 34Alimera Sciences (F) …………………………… 19Alkomohr Biotech Oy Ltd. (FIN) ……………… 22Allecra Therapeutics GmbH (GER) …………… 25Almirall S. A. (E) ………………………………… 18Altia Oy (FIN) …………………………………… 22Amgen Inc. (USA) …………………………… 8, 33Amplidiag Oy (FIN) …………………………… 20Amsterdam Molecular Therapeutics (NL) …… 36Amundi Private Equity Funds (F) ……………… 26Apogenix AG (GER) …………………………… 34ASSOBIOTEC (IT) ……………………………… 15Associated British Food (UK) ………………… 22Astellas Pharma Europe B.V. (NL) …………… 20AstraZeneca AB (S/UK)……………………… 19, 33Auris Medical (CH) …………………………… 25Avalon Ventures (USA) ………………………… 33AyoxxA Biosystems GmbH (GER) …………… 34

BBASF SE (GER) ………………………………… 47Basilea Pharmaceutica (CH) …………………25, 33Bavarian Nordic A/S (DK) …………………… 19, 22Bayer AG (GER) ……………………………… 14, 18Bayer CropScience GmbH (GER) ……………… 24Berlin Partner GmbH (GER) ……………………… 9Biocartis SA (CH) ……………………………… 44BIOCOM AG (GER) …………………………… 45Biocon (IND) ……………………………………… 8Biohit Oyj (FIN) ………………………………… 29BioInvent International AB (S) ………………… 23BioMedInvest AG (CH) ………………………… 21Blue Cross-Blue Shield (USA) ………………… 33Boehmert & Boehmert (GER) ………………… 40Boehringer Ingelheim (GER) …………… 7, 8, 28Bone Therapeutics (B) ………………………… 18Borregaard Ind. Ltd (N) ………………………… 23Brain AG (GER) ………………………………34, 36Bristol-Myers Squibb (USA) …………… 18, 22, 33Brockmeyer Biopharma GmbH (GER) ………… 47

CCaixa Capital Biomed (E) ……………………… 29Carbios SAS (F) ………………………………… 26Cardio3 Biosciences (B) ……………………… 18CD-Venture GmbH (GER) ……………………… 21Celgene Europe Ltd. (UK) ……………………20, 36Cell2B (PT) ……………………………………… 20Celltrion (KR) ……………………………………… 8Cevec Pharma GmbH (GER) ………………… 34ChemAxon Ltd (HUN) ………………………… 30Chiroscience Group plc (UK) ………………… 47Chroma Therapeutics Ltd (UK) ……………… 47Cipla Ltd. (VRC) …………………………………… 8Clavis Pharma ASA (N) ………………………… 47Clever Consult (B) ………………………………… 3Clinigen Group Ltd. (UK) ……………………… 47co.don AG (GER) ……………………………… 34

Minoryx Therapeutics S.L. (E) ………………… 29Mobidiag Oy (FIN) ……………………………… 20Mologen AG (GER) …………………………18, 34Nicox S.A. (F) …………………………………… 19nova-Institut GmbH (GER) …………………… 14Novartis AG (CH) ……………………………… 14Novartis Venture Fund (CH) …………………26, 36Novo Nordisk A/S (DK) ………………………23, 36

o/pOrchid Biosciences Europe LTD (IND) ……… 25Orexo AB (S) …………………………………… 19Oxford Glycoscience (UK) …………………… 47Panmure Gordon (UK) ………………………… 20Pfizer Ltd. (USA) ……………………………… 8, 20PharmaMar S.A. (E) …………………………28, 29Pharming Group N.V. (NL) ………………… 19, 27Pharmium Securities (F) ……………………… 19Phenex Pharmaceuticals AG (GER) …………… 34Pioneer Hi-Bred International Inc. (USA) …… 10Prestwick Chemical (F) ………………………… 12Priaxon AG (GER) ……………………………… 25Prime Therapeutics LLC (USA) ………………… 33Probi AB (S) …………………………………… 47Probiodrug AG (GER) ………………………… 34Pronova Biopharma (N) ……………………… 47ProQinase GmbH (GER) ……………………… 12ProStrakan Group plc (UK) …………………… 47ProtAffin Biotechnologie AG (A) ……………… 20Proteros Biostructures GmbH (GER) ………… 34

r/sRaupach & Wollert-Elmendorff (GER) ………… 37Roal Oy (FIN) …………………………………… 22Roche Diagnostics GmbH (GER) ………… CP2, 37Röhm GmbH & Co. KG (GER) ………………… 22Salans FMC SNR Denton (USA/GER) ………35, 37Sandoz Biopharmaceuticals (CH) …………… 47Sanofi SA (F) …………………………………… 30Santaris Pharma A/S (DK) …………………… 21Santarus Inc. (USA) ………………………… 19, 27Santhera Pharmaceuticals (CH) ……… 18, 26, 47SARomics Biostructures (S) …………………… 12SBH Diagnostics Inc. (CDN) …………………… 23Scancell Holding plc. (UK) …………………… 47Serichim S.r.l. (IT) ……………………………… 27Silence Therapeutics AG (GER) ……………… 34Silicon Biosystems S.p.A. (IT) ………………… 34Sofinnova (F) …………………………………… 25Subitec GmbH (GER) ………………………… 34Suppremol GmbH (GER) ……………………… 47Swedish Orphan Biovitrum AB (S) …………… 47

tt-cell Europe GmbH (GER) …………………… 34Tesco (UK) ……………………………………… 27Teva Pharmaceutical Industries Ltd. (IL) ………… 8Theradiag SA (F) ……………………………… 27Thrombogenics (B) …………………………… 19Topo Target A/S (DK) ………………………… 47Torviscosa (IT) ………………………………… 27

U/VuniQure BV (NL) ……………………………… 36Versant Ventures (USA)………………………… 26ViroPharma Sprl (B) …………………………… 20 Vossius und Partner (GER) …………………… 15

W/y/ZWellington Partners (GER) …………………… 26Wilex AG (GER) ………………………………… 34Ylichron Srl (IT) ………………………………… 29Zeltia Group (E) ………………………… 11, 28, 29

Cobra Biologics (UK) …………………………… 17conogenetix biosciences GmbH (GER) ……… 34Cooley Ventue (USA) ………………………… 36Core Informatics (USA) ………………………… 30Corimmun GmbH (GER) ……………………… 36Creabilis Therapeutics S.p.A. (LUX) …………… 27Curetis AG (GER) ……………………………… 21Curevac GmbH (GER) ………………………… 34

d/eDermatools Biotech GmbH (GER) …………… 34Deutsche Messe AG (GER) …………………… CP3Distance a. Independent Studies Center (GER) …… 13DNA Electronics (UK) ………………………… 24Dompé Farmaceutici S.p.A. (I) ………………… 20Edmond de Rothschild Investment (F) ……25, 26Ernst & Young (UK) …………………… 33, 43, 44Eyevensys SA (F) ……………………………36, 47

F/GF. Hoffmann - La Roche AG (CH) 8, 18, 19, 21, 24Forbion Capital Partners (NL) ………………… 25Forest Laboratories Inc. (USA) ………………… 18Formycon AG (GER) …………………………… 47Fujifilm Diosynth Biotechnologies (UK) ……… 27Galapagos NV (B) …………………………… 27, 33Genewave SAS (F) …………………………… 20Genmab A/S (DK) ……………………………23, 33GenSight Biologics (F) ………………………… 26Genticel S.A. (F) ……………………………… 26Genzyme Corp. (USA) ………………………20, 47Gerresheimer AG (GER) ……………………… 30GlaxoSmithKline (UK) ………………………20, 33Grünecker Patent- und Rechtsanwälte (GER) … 14

HHBM Healthcare Investments (Cayman) (UK) 25HBM Partners AG (CH) ………………………… 21Hexal AG (GER) ………………………………… 47High-Tech Gründerfonds Managm. (GER) … 19, 34Horizon Discovery Ltd. (UK) …………………… 26Hospira One 2 One Global Pharmaceutical (USA) CP4

i/JIBM Corp. (USA) ……………………………24, 30Illumina Inc. (USA) ……………………………… 24IMS Health (UK)…………………………………… 6Index Pharmaceuticals AB (S) ………………… 18Index Ventures (CH) …………………………… 26ING BHF-BANK AG (GER) ……………………… 47Innovation Norway……………………………… 23Janssen Pharmaceutica N.V. (B) ……………… 28Johnson & Johnson (USA) …………………… 33Jones Day (B) ………………………………… 37

K/LKarolinska Development AB (S) ……………… 47Kempen & Co (NL) …………………………… 39Keygene N.V. (NL) ……………………………… 24KfW Bankengruppe (GER) …………………… 21Knoll AG (GER) ………………………………… 47Life Science Austria LISA (A) …………………… 41Life Sciences Partners (GER) ………………… 21Life Technologies GmbH (GER) ………………… 7Lonza AG (CH) …………………………………… 8

m/NMagforce Nanotechnologies AG (GER) ……… 19Marinomed Biotechnologie GmbH (A) ……… 18Medeva BV (NL) ……………………………… 47Merck & Co. (USA) ……………………………… 33Merck Serono (CH) …………………………… 44Mercodia AB (S) ………………………………… 23Merrill Lynch (USA) …………………………… 23

FREE EXCERPT

biotechnica.de

For detailed information simply go to:www.biotechnica.de/en/award

EUROPEAN BIOTECHNICA AWARD 2013

Winner of the EUROPEAN BIOTECHNICA AWARD 2011: Unitectra AG

Don’t miss this year’s award presentation: 10th EUROPEAN BIOTECHNICA AWARD, given in recognition of a European biotech or life sciences organization

with proven expertise and success in achieving “Integration of Biotechnology into the Industry”

One of Europe’s most important biotechnology prizes, awarded by an international jury

Monday, 7 October 2013, on the occasion of the BIOTECHNICA Opening Ceremony at the Hannover Exhibition

Center (Hannover, Germany)

Save the date:

7 October 2013

DM_485_2013_bio14_award_anzeige_210_275mm.indd 1 03.05.13 08:55

One 2 One Journal Ad - 8.25x10.875 (L. Science Leader)

Our comfort zone isglobal parenteral manufacturing

Parenteral Contract Manufacturing Service of Hospira P11-3517A-Jan., 12

Parenteral Contract Manufacturing Service of Hospira

• Betalactams• Controlled Substances• Sterile Compounding• Single-Use Technology

• Lyophilization

• Global Regulatory Services

• QP Release

• Biologics• Highly Potent

Drugs

• Cytotoxics

Your Parenteral Comfort Zone

Zagreb, Croatia

Chennai, India

Discover your comfort zone at one2onecmo.comGet your custom report online or contact One 2 One.

Call +1-224-212-2267 or +44 (0) 1926 835 554 or e-mail one2one@hospira.com